Symbols

XTLB

Xtl Biopharmaceuticals·NASDAQ

--(--)

Signals Analysis

Bullish signal 1

Bearish signal 0

Stock Price Surged Significantly

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About XTLB

Xtl Biopharmaceuticals Ltd.

A biopharmaceutical company that developing drugs for the treatment of autoimmune diseases

Industry

Pharmaceutical

Established Date

03/09/1993

Listing Date

07/15/2013

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.xtlbio.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

26 Ben-Gurion St. Ramat Gan 5112001 Israel

Business

Engaged in the acquisition and research and development of pharmaceutical products.

Introduction

Xtl Biopharmaceuticals Ltd., established under the laws of Israel on March 9, 1993, is a biopharmaceutical company focused on acquiring and developing medicines to meet unmet medical needs, especially for diseases such as multiple myeloma (MM), schizophrenia and hepatitis C. Through its subsidiary InterCure, the company develops and sells home treatment devices for non-drug and non-invasive treatment of various diseases, including hypertension, heart failure, insomnia and mental stress. In addition, Xtl, through its wholly-owned subsidiary The Social Proxy, engages in intellectual property activities related to agency and data collection. The company holds a license from Yeda for hCDR1, a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). Since its inception, Xtl has focused on developing technologies and drug candidates, acquiring compounds in the preclinical and clinical stages, and raising capital, but has yet to achieve drug sales.

Company Financials

EPS

XTLB has released its 2022 Q2 earnings. EPS was reported at 0, versus the expected 0, meeting expectations. The chart below visualizes how XTLB has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

XTLB has released its 2024 Q4 earnings report, with revenue of 289.00K, reflecting a YoY change of NaN%, and net profit of -255.00K, showing a YoY change of 10.21%. The Sankey diagram below clearly presents XTLB's revenue sources and cost distribution.